---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-010091"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:57:40.475548+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lexeo Therapeutics reports positive interim Phase 1/2 clinical data for LX2020 in PKP2-ACM

## Summary
- LX2020 generally well tolerated in 10 participants; no clinically significant complement activation observed
- Mean PKP2 protein expression increased 93% in low-dose (n=2) and 162% in high-dose cohorts (n=5) by western blot
- Non-sustained ventricular tachycardia reduced 22% (mean) in high-dose cohort (n=5); PVCs improved 14%
- 4 of 5 high-dose participants reported improvement on the PGIC patient-reported outcome scale
- HEROIC-PKP2 enrollment completed Q4 2025; 12-month data for all high-dose participants expected Q4 2026

## SEC filing metadata
- accession: 0001193125-26-010091
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000119312526010091/0001193125-26-010091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000119312526010091/lxeo-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-010091
- JSON: https://secwatch.observer/filing/0001193125-26-010091.json
- Plain text: https://secwatch.observer/filing/0001193125-26-010091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.